These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29808339)

  • 1. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
    Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
    Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
    Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.
    Fürtjes G; Köchling M; Peetz-Dienhart S; Wagner A; Heß K; Hasselblatt M; Senner V; Stummer W; Paulus W; Brokinkel B
    J Neurooncol; 2016 Oct; 130(1):79-87. PubMed ID: 27465278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.
    Mirian C; Duun-Henriksen AK; Juratli T; Sahm F; Spiegl-Kreinecker S; Peyre M; Biczok A; Tonn JC; Goutagny S; Bertero L; Maier AD; Møller Pedersen M; Law I; Broholm H; Cahill DP; Brastianos P; Poulsgaard L; Fugleholm K; Ziebell M; Munch T; Mathiesen T
    J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):378-387. PubMed ID: 32041819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter mutations in primary and secondary WHO grade III meningioma.
    Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
    Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
    Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
    J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
    Goutagny S; Nault JC; Mallet M; Henin D; Rossi JZ; Kalamarides M
    Brain Pathol; 2014 Mar; 24(2):184-9. PubMed ID: 24261697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas.
    Ferraro DJ; Funk RK; Blackett JW; Ju MR; DeWees TA; Chicoine MR; Dowling JL; Rich KM; Drzymala RE; Zoberi I; Simpson JR; Jaboin JJ
    Radiat Oncol; 2014 Jan; 9():38. PubMed ID: 24467972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
    Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
    Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome.
    Bertero L; Dalla Dea G; Osella-Abate S; Botta C; Castellano I; Morra I; Pollo B; Calatozzolo C; Patriarca S; Mantovani C; Rudà R; Tardivo V; Zenga F; Garbossa D; Papotti M; Soffietti R; Ricardi U; Cassoni P
    J Neuropathol Exp Neurol; 2019 Mar; 78(3):248-256. PubMed ID: 30689922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARID1A and TERT promoter mutations in dedifferentiated meningioma.
    Abedalthagafi MS; Bi WL; Merrill PH; Gibson WJ; Rose MF; Du Z; Francis JM; Du R; Dunn IF; Ligon AH; Beroukhim R; Santagata S
    Cancer Genet; 2015 Jun; 208(6):345-50. PubMed ID: 25963524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management.
    Gousias K; Schramm J; Simon M
    J Neurosurg; 2016 Sep; 125(3):551-60. PubMed ID: 26824369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WHO grade II and III meningiomas: a study of prognostic factors.
    Durand A; Labrousse F; Jouvet A; Bauchet L; Kalamaridès M; Menei P; Deruty R; Moreau JJ; Fèvre-Montange M; Guyotat J
    J Neurooncol; 2009 Dec; 95(3):367-375. PubMed ID: 19562258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome.
    Karsy M; Burnett B; Di Ieva A; Cusimano MD; Jensen RL
    J Neurosurg; 2018 Mar; 128(3):657-666. PubMed ID: 28362240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
    Stögbauer L; Stummer W; Senner V; Brokinkel B
    Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution.
    Hua L; Zhu H; Li J; Tang H; Kuang D; Wang Y; Tang F; Chen X; Zhou L; Xie Q; Gong Y
    J Neurosurg; 2018 Jun; 128(6):1698-1706. PubMed ID: 28820306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.